4-HYDROXY-6-(3-HYDROXY-8-(HYDROXYMETHYL)-2,6,10,12-TETRAMETHYLOCTADECA-4,6,9-TRIEN-2-YL)-3-(2-HYDROXYETHYL)-2H-PYRAN-2-ONE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	FFTOWXZOJFEINY-YJBWKGOYSA-N
Smiles	CCCCCCC(C)C\C(=C/C(CO)\C=C(/C)\C=C\C(O)C(C)(C)C1=CC(=C(CCO)C(=O)O1)O)\C
InChI	InChI=1S/C30H48O6/c1-7-8-9-10-11-21(2)16-23(4)18-24(20-32)17-22(3)12-13-27(34)30(5,6)28-19-26(33)25(14-15-31)29(35)36-28/h12-13,17-19,21,24,27,31-34H,7-11,14-16,20H2,1-6H3/b13-12+,22-17+,23-18-

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C30H48O6
Molecular Weight	504.7
AlogP	5.87
Hydrogen Bond Acceptor	6.0
Hydrogen Bond Donor	4.0
Number of Rotational Bond	16.0
Polar Surface Area	107.22
Molecular species	ACID
Aromatic Rings	0.0
Heavy Atoms	36.0

Assay Description	Organism	Bioactivity	Reference
Antifungal activity against Rhodotorula glutinis assessed as growth inhibition at 50 ug/ml after 24 to 72 hr by broth dilution method	Rhodotorula glutinis	None
Antifungal activity against Meyerozyma guilliermondii assessed as growth inhibition at 50 ug/ml after 24 to 72 hr by broth dilution method	Meyerozyma guilliermondii	None

Cross References

Resources	Reference
ChEMBL	CHEMBL2269329
PubChem	54676271

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).